



US009636299B2

(12) **United States Patent**  
**Bhattacharjee**

(10) **Patent No.:** **US 9,636,299 B2**  
(45) **Date of Patent:** **May 2, 2017**

(54) **METHOD FOR TREATING DIABETIC RETINOPATHY**

(71) Applicant: **XAVIER UNIVERSITY OF LOUISIANA**, New Orleans, LA (US)

(72) Inventor: **Partha S. Bhattacharjee**, New Orleans, LA (US)

(73) Assignee: **XAVIER UNIVERSITY OF LOUISIANA**, New Orleans, LA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/388,412**

(22) PCT Filed: **Mar. 15, 2013**

(86) PCT No.: **PCT/US2013/031911**

§ 371 (c)(1),

(2) Date: **Sep. 26, 2014**

(87) PCT Pub. No.: **WO2013/148305**

PCT Pub. Date: **Oct. 3, 2013**

(65) **Prior Publication Data**

US 2015/0045296 A1 Feb. 12, 2015

#### **Related U.S. Application Data**

(60) Provisional application No. 61/617,269, filed on Mar. 29, 2012, provisional application No. 61/679,480, filed on Aug. 3, 2012.

(51) **Int. Cl.**

**A61K 9/00** (2006.01)

**A61K 38/17** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 9/0048** (2013.01); **A61K 38/1709** (2013.01)

(58) **Field of Classification Search**

CPC ..... **A61K 38/1709**; **A61K 9/0048**

See application file for complete search history.

(56) **References Cited**

#### **U.S. PATENT DOCUMENTS**

7,691,382 B2 4/2010 Dobson

#### **FOREIGN PATENT DOCUMENTS**

WO WO 2007038453 A2 \* 4/2007 ..... A61K 31/00

#### **OTHER PUBLICATIONS**

Paolo S. Silva, Diabetic Retinopathy: Effect of Medications on Onset and Progression : Antiangiogenic Agents, Medscape Multispecialty, 2010, pp. 1-2.\*

Ning Cheung, Diabetic retinopathy, Lancet 2010; 376: 124-36.\*  
International Search Report from corresponding PCT/US2013/031911, mailed Jul. 2013.

Bhattacharjee et al., "A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis," PLoS One. vol. 6, No. 1, Article No. e15905, 2011, pp. 1-9.

Schulter et al., "Impact of apolipoprotein(a) on in vitro angiogenesis," Arteriosclerosis, Thrombosis, and Vascular Biology. vol. 21, No. 3, 2001, pp. 433-438.

Usui et al., "Gene expression profile in corneal neovascularization identified by immunology related macroarray," Molecular Vision. vol. 10, 2004, pp. 832-836.

Conley et al., "Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy," Human Molecular Genetics, vol. 14, No. 14, 2005, pp. 1991-2002.

Bhattacharjee et al., "High-glucose-induced endothelial cell injury is inhibited by a peptide derived from human apolipoprotein E", PLoS One, vol. 7, No. 12, Article No. e52152, Dec. 19, 2012, pp. 1-8.

Anderson DH, Ozaki S, Nealon M, Neitz J, Mullins RF, Hageman GS, Johnson LV. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. Am J Ophthalmol. 2001;131(6):767-81.

Bhatt LK, Addepalli V. Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats. Am J Transl Res. 2010;2(2):181-9.

Bhattacharjee PS, Huq TS, Mandal TK, Graves RA, Muniruzzaman S, Clement C, McFerrin HE, Hill JM. A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis. PLoS One. 2011;6(1):e15905.

Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, Brandt R, Ferro V, Bytheway I. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011;104(4):635-42.

Dyer CA, Cistola DP, Parry GC, Curtiss LK. Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor. J Lipid Res. 1995;36(1):80-8.

Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, Vlodavsky I. Heparanase as mediator of angiogenesis: mode of action. FASEB J. 2001;15(9):1661-3.

Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540-53.

Huet E, Vallée B, Delbé J, Mourah S, Pruliere-Escabasse V, Tremouilleres M, Kadomatsu K, Doan S, Baudouin C, Menashi S, Gabison EE. EMMPRIN modulates epithelial barrier function through a MMP-mediated occludin cleavage: implications in dry eye disease. Am J Pathol. 2011;179(3):1278-86.

Ji ZS, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem. 1994;269(18):13421-8.

Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB. Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity. FEBS Journal. 2007;274(17):4511-4525.

(Continued)

*Primary Examiner* — Hasan Ahmed

*Assistant Examiner* — Erinne Dabkowski

(74) *Attorney, Agent, or Firm* — McBee Moore

Woodward & Vanik IP, LLC

(57)

#### **ABSTRACT**

Compositions useful for treatment of retinal pathologies, including diabetic retinopathy, and methods of making and using said compositions, are provided.

**2 Claims, 15 Drawing Sheets**